Beyond Air ( (XAIR) ) has released its Q3 earnings. Here is a breakdown of the information Beyond Air presented to its investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company engaged in utilizing nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors, with its flagship product, LungFit PH, approved for use in several countries.
The company reported a significant increase in revenue for its fiscal third quarter of 2025, marking a 34% rise from the previous quarter, and has achieved important regulatory milestones, including CE Mark approval for LungFit PH in Europe and market authorization in Australia.
Beyond Air’s financial performance highlights include a revenue of $1.1 million for the quarter, driven by increased demand for LungFit PH, though it continues to operate at a loss due to high costs related to device depreciation and upgrades. The company also secured two distributor partnerships in the Middle East and anticipates further regulatory approvals in eight countries.
Strategic developments include the completion of a Phase 1a trial for its ultra-high concentration Nitric Oxide therapy aimed at treating solid tumors, with ongoing trials in Israel. Additionally, the company’s NeuroNOS program has welcomed a Nobel laureate to its advisory board to advance treatments for autism spectrum disorder.
Looking forward, Beyond Air remains optimistic about its revenue growth trajectory and is poised to expand its market presence internationally, supported by its cash conservation strategy and anticipated sales increases, ensuring financial stability well into 2026.
